

# Jordi Remon

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6923370/publications.pdf>

Version: 2024-02-01

55  
papers

2,314  
citations

331642

21  
h-index

223791

46  
g-index

57  
all docs

57  
docs citations

57  
times ranked

3478  
citing authors

#	ARTICLE	IF	CITATIONS
1	Hyperprogressive Disease in Patients With Advanced Non-Small Cell Lung Cancer Treated With PD-1/PD-L1 Inhibitors or With Single-Agent Chemotherapy. <i>JAMA Oncology</i> , 2018, 4, 1543.	7.1	567
2	First-Line Immunotherapy for Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2022, 40, 586-597.	1.6	312
3	Crizotinib-Resistant <i>ROS1</i> Mutations Reveal a Predictive Kinase Inhibitor Sensitivity Model for <i>ROS1</i> - and <i>ALK</i> -Rearranged Lung Cancers. <i>Clinical Cancer Research</i> , 2016, 22, 5983-5991.	7.0	124
4	Immune Checkpoint Inhibitors in Thoracic Malignancies: Review of the Existing Evidence by an IASLC Expert Panel and Recommendations. <i>Journal of Thoracic Oncology</i> , 2020, 15, 914-947.	1.1	119
5	Acquired Resistance Mutations to ALK Inhibitors Identified by Single Circulating Tumor Cell Sequencing in <i>ALK</i> -Rearranged Non-Small-Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2019, 25, 6671-6682.	7.0	95
6	LKB1/STK11 mutations in non-small cell lung cancer patients: Descriptive analysis and prognostic value. <i>Lung Cancer</i> , 2017, 112, 62-68.	2.0	92
7	The APPLE Trial: Feasibility and Activity of AZD9291 (Osimertinib) Treatment on Positive PLasma T790M in EGFR -mutant NSCLC Patients. EORTC 1613. <i>Clinical Lung Cancer</i> , 2017, 18, 583-588.	2.6	84
8	EGFR exon 20 insertions in advanced non-small cell lung cancer: A new history begins. <i>Cancer Treatment Reviews</i> , 2020, 90, 102105.	7.7	80
9	Circulating T-cell Immunosenescence in Patients with Advanced Non-small Cell Lung Cancer Treated with Single-agent PD-1/PD-L1 Inhibitors or Platinum-based Chemotherapy. <i>Clinical Cancer Research</i> , 2021, 27, 492-503.	7.0	76
10	Common <i>EGFR</i> -mutated subgroups (Del19/L858R) in advanced non-small-cell lung cancer: chasing better outcomes with tyrosine kinase inhibitors. <i>Future Oncology</i> , 2015, 11, 1245-1257.	2.4	66
11	Successes and failures: what did we learn from recent first-line treatment immunotherapy trials in non-small cell lung cancer?. <i>BMC Medicine</i> , 2017, 15, 55.	5.5	65
12	Circulating Tumor Cells with Aberrant <i>ALK</i> Copy Number Predict Progression-Free Survival during Crizotinib Treatment in <i>ALK</i> -Rearranged Non-Small Cell Lung Cancer Patients. <i>Cancer Research</i> , 2017, 77, 2222-2230.	0.9	64
13	Are liquid biopsies a surrogate for tissue EGFR testing?. <i>Annals of Oncology</i> , 2018, 29, i38-i46.	1.2	61
14	Advanced-Stage Non-Small Cell Lung Cancer: Advances in Thoracic Oncology 2018. <i>Journal of Thoracic Oncology</i> , 2019, 14, 1134-1155.	1.1	61
15	Circulating Tumor DNA Analysis for Patients with Oncogene-Addicted NSCLC With Isolated Central Nervous System Progression. <i>Journal of Thoracic Oncology</i> , 2020, 15, 383-391.	1.1	58
16	Immunotherapy for oncogenic-driven advanced non-small cell lung cancers: Is the time ripe for a change?. <i>Cancer Treatment Reviews</i> , 2018, 71, 47-58.	7.7	37
17	Current Panorama and Challenges for Neoadjuvant Cancer Immunotherapy. <i>Clinical Cancer Research</i> , 2020, 26, 5068-5077.	7.0	34
18	Current treatment and future challenges in <i>ROS1</i> - and <i>ALK</i> -rearranged advanced non-small cell lung cancer. <i>Cancer Treatment Reviews</i> , 2021, 95, 102178.	7.7	34

#	ARTICLE	IF	CITATIONS
19	Liquid biopsy in oncology: a consensus statement of the Spanish Society of Pathology and the Spanish Society of Medical Oncology. <i>Clinical and Translational Oncology</i> , 2020, 22, 823-834.	2.4	29
20	Symptomatic leptomeningeal metastasis improvement with nivolumab in advanced non-small cell lung cancer patient. <i>Lung Cancer</i> , 2017, 108, 72-74.	2.0	28
21	Crystal digital droplet PCR for detection and quantification of circulating EGFR sensitizing and resistance mutations in advanced non-small cell lung cancer. <i>PLoS ONE</i> , 2017, 12, e0183319.	2.5	26
22	Activity and safety of oral etoposide in pretreated patients with metastatic or recurrent thymic epithelial tumors (TET): A single-institution experience. <i>Lung Cancer</i> , 2016, 99, 111-116.	2.0	21
23	PECATI: A Multicentric, Open-Label, Single-Arm Phase II Study to Evaluate the Efficacy and Safety of Pembrolizumab and Lenvatinib in Pretreated B3-Thymoma and Thymic Carcinoma Patients. <i>Clinical Lung Cancer</i> , 2022, 23, e243-e246.	2.6	20
24	Outcomes in oncogenic-addicted advanced NSCLC patients with actionable mutations identified by liquid biopsy genomic profiling using a tagged amplicon-based NGS assay. <i>PLoS ONE</i> , 2020, 15, e0234302.	2.5	13
25	Emerging Systemic Treatment Perspectives on Brain Metastases: Moving Toward a Better Outlook for Patients. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2022, 42, 147-165.	3.8	12
26	Immunotherapy Moves to the Early-Stage Setting in Non-Small Cell Lung Cancer: Emerging Evidence and the Role of Biomarkers. <i>Cancers</i> , 2020, 12, 3459.	3.7	11
27	Lung Cancer in Spain. <i>Journal of Thoracic Oncology</i> , 2021, 16, 197-204.	1.1	11
28	Somatic and Germline BRCA 1 and 2 Mutations in Advanced NSCLC From the SAFIRO2-Lung Trial. <i>JTO Clinical and Research Reports</i> , 2020, 1, 100068.	1.1	10
29	Targeted therapy moves to earlier stages of non-small-cell lung cancer: emerging evidence, controversies and future challenges. <i>Future Oncology</i> , 2021, 17, 4011-4025.	2.4	10
30	Non-small-cell lung cancer: what are the benefits and challenges of treating it with immune checkpoint inhibitors?. <i>Immunotherapy</i> , 2019, 11, 1149-1160.	2.0	9
31	Paving the Way for Long-Term Survival in Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2021, 39, 2321-2323.	1.6	9
32	Sequential blinded treatment decisions in ALK-positive non-small cell lung cancers in the era of precision medicine. <i>Clinical and Translational Oncology</i> , 2020, 22, 1425-1429.	2.4	8
33	Osimertinib Should be the Standard of Care for the Adjuvant Therapy of Stage IB to IIIA EGFR-Mutant NSCLC. <i>Journal of Thoracic Oncology</i> , 2021, 16, 368-370.	1.1	8
34	How to optimize the incorporation of immunotherapy in trials for oligometastatic non-small cell lung cancer: a narrative review. <i>Translational Lung Cancer Research</i> , 2021, 10, 3486-3502.	2.8	8
35	Immune checkpoint inhibitors a new player in the therapeutic game of mesothelioma: New reality with new challenges. <i>Cancer Treatment Reviews</i> , 2021, 99, 102250.	7.7	6
36	SEOM-GECP-GETTHI Clinical Guidelines for the treatment of patients with thymic epithelial tumours (2021). <i>Clinical and Translational Oncology</i> , 2022, 24, 635-645.	2.4	6

#	ARTICLE	IF	CITATIONS
37	The efficacy of immune checkpoint inhibitors in thoracic malignancies. <i>European Respiratory Review</i> , 2021, 30, 200387.	7.1	5
38	Targeting genome integrity dysfunctions impedes metastatic potency in non-small-cell lung cancer circulating tumor cell-derived eXplants. <i>JCI Insight</i> , 2022, .	5.0	5
39	Upfront osimertinib “winner takes it all?”. <i>Nature Reviews Clinical Oncology</i> , 2020, 17, 202-203.	27.6	4
40	Antiangiogenic Second-line Lung cancer Meta-Analysis on individual patient data in non-small cell lung cancer: ANSELMA. <i>European Journal of Cancer</i> , 2022, 166, 112-125.	2.8	4
41	Future Genetic/Genomic Biomarker Testing in Non-Small Cell Lung Cancer. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2017, 37, 12-17.	3.8	3
42	Dynamics of eligibility criteria for central nervous system metastases in non-small cell lung cancer randomized clinical trials over time: A systematic review. <i>Critical Reviews in Oncology/Hematology</i> , 2021, 166, 103460.	4.4	3
43	Malignant pleural mesothelioma: new guidelines make us stronger for defeating this disease. <i>Annals of Oncology</i> , 2022, 33, 123-125.	1.2	3
44	CheckMate 153 study: are age and performance status relevant for immune checkpoint inhibitor efficacy?. <i>Translational Lung Cancer Research</i> , 2019, 8, S464-S467.	2.8	2
45	Radiogenomics in 332 metastatic non-small cell lung cancer (NSCLC) patients.. <i>Journal of Clinical Oncology</i> , 2016, 34, 11563-11563.	1.6	2
46	Who benefits from consolidation durvalumab in stage III non-small cell lung cancer?. <i>European Journal of Cancer</i> , 2022, 167, 149-151.	2.8	2
47	Peritoneal recurrence of thymoma treated by surgery and hyperthermic intraperitoneal chemotherapy. <i>Lung Cancer</i> , 2017, 111, 59-60.	2.0	1
48	Update on Targeted Therapies for Advanced Non-Small Cell Lung Cancer: Durvalumab in Context. <i>Oncotargets and Therapy</i> , 2020, Volume 13, 6885-6896.	2.0	1
49	Chemotherapy + PD-1/PD-L1 Blockade Should Not Be the Preferred Option in the Neoadjuvant Therapy of NSCLC. <i>Journal of Thoracic Oncology</i> , 2022, 17, 499-502.	1.1	1
50	ALK rearranged lung cancer: TKI treatment and outcome. , 2021, , 31-53.		0
51	Evaluation of liquid biopsies for molecular profiling and monitoring in non-small cell lung cancer (NSCLC) patients.. <i>Journal of Clinical Oncology</i> , 2016, 34, 11533-11533.	1.6	0
52	ALK-amplified circulating tumor cells as a surrogate marker for crizotinib benefit in ALK-rearranged non-small cell lung cancer patients.. <i>Journal of Clinical Oncology</i> , 2016, 34, 11515-11515.	1.6	0
53	Differential epithelial and mesenchymal CTC profiling according to non-small cell lung cancer (NSCLC) molecular subtype.. <i>Journal of Clinical Oncology</i> , 2016, 34, e23093-e23093.	1.6	0
54	Editorial: Understanding the Interplay Between the Tumor Immune Microenvironment and Genetic Alterations in Thoracic Malignancies. <i>Frontiers in Oncology</i> , 2022, 12, 871544.	2.8	0

#	ARTICLE	IF	CITATIONS
55	Clinical utility and outcomes impact of crystal digital PCR of sensitizing and resistance EGFR mutations in patients with advanced non-small cell lung cancer. Clinical Lung Cancer, 2022, , .	2.6	0